Abstract
Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, the prognostic factors, and their underlying mechanisms is crucial. In this review, we summarized the latest advancements in this field. Within the tumor microenvironment, PD-L1 expression is commonly utilized to predict response. Moreover, the characteristics of tumor-infiltrating lymphocytes are associated with the effectiveness of immunotherapy. Preclinical studies have identified stimulatory dendritic cells, conventional dendritic cells, and macrophages as potential biomarkers. The emergence of single-cell sequencing and spatial transcriptomics has provided invaluable insights into tumor heterogeneity through the lens of single-cell profiling and spatial distribution. With the widespread adoption of next-generation sequencing, certain genomic characteristics, including tumor mutational burden, copy number alterations, specific genes (TP53, CTNNB1, and GZMB), and signaling pathways (WNT/β-catenin) have been found to correlate with prognosis. Furthermore, clinical features such as tumor size, number, and metastasis status have demonstrated prognostic value. Notably, common indicators such as the Child-Pugh score and Eastern Cooperative Oncology Group score, which are used in patients with liver diseases, have shown potential. Similarly, commonly employed laboratory parameters such as baseline transforming growth factor beta, lactate dehydrogenase, dynamic changes in alpha-fetoprotein (AFP) and abnormal prothrombin, CRAFITY score (composed of C-reactive protein and AFP), and immune adverse events have been identified as predictive biomarkers. Novel imaging techniques such as EOB-MRI and PET/CT employing innovative tracers also have potential. Moreover, liquid biopsy has gained widespread use in biomarker studies owing to its non-invasive, convenient, and highly reproducible nature, as well as its dynamic monitoring capabilities. Research on the gut microbiome, including its composition, dynamic changes, and metabolomic analysis, has gained considerable attention. Efficient biomarker discovery relies on continuous updating of treatment strategies. Next, we summarized recent advancements in clinical research on HCC immunotherapy and provided an overview of ongoing clinical trials for contributing to the understanding and improvement of HCC immunotherapy.
Similar content being viewed by others
Background
Cancer-related deaths due to hepatocellular carcinoma (HCC) rank fourth worldwide, presenting an abysmal outlook. Due to its insidious onset and asymptomatic nature, most patients are not diagnosed until later stages [1,2,3].
Immunotherapy is supported by the immune tolerance of the liver and the predominantly immunosuppressed microenvironment of HCC [4]. Since 2017, programmed death-1 (PD-1) inhibitors have been approved as second-line therapies for advanced hepatocellular carcinoma (aHCC). Although an encouraging response rate has been observed [5, 6], they have been unsuccessful due to insufficient statistical significance in subsequent phase III randomized clinical trials (RCTs) [7, 8]. Combination therapy is develo** rapidly. Basic research has shown that the PD-1 inhibitor combined with tyrosine kinase inhibitors (TKIs) or anti-vascular endothelial growth factor (VEGF) antibody can enhance antitumor efficacy by increasing lymphocyte infiltration, weakening the immunosuppressive state, and promoting the normalization of blood vessels [9,10,11]. In clinical studies, the combination of atezolizumab, a programmed death ligand 1 (PD-L1) inhibitor, and bevacizumab, an anti-VEGF inhibitor, significantly prolonged progression-free survival (PFS) and overall survival (OS) compared with the classic treatment; thus, this combined treatment represents a new systemic treatment for HCC [12].
Good efficacy has been demonstrated in PD-1/PD-L1 inhibitor-based systemic therapy for aHCC; however, only a fraction of patients (15–40%) have benefited. Moreover, a significant percentage of patients who undergo treatment encounter disease progression (approximately 20–30%). Identifying biomarkers and prognostic factors for immunotherapy efficacy and their underlying mechanisms is crucial for patient selection, stratified management, and future related clinical research. Therefore, this review focuses mainly on research progress on biomarkers and prognostic factors of aHCC.
Biomarkers of hepatocellular carcinoma immunotherapy
Tumor microenvironment
PD-L1 expression
Even though PD-L1 expression remains a topic of debate in immunotherapy [13], most studies still support it as a predictor of response and prognosis (details are summarized in Table 1). According to CheckMate 040, PD-L1 expression is an effective biomarker. With expression ≥ 1% as the cut-off value for defining PD-L1 positive expression, positive individuals had a more promising objective response rate (ORR) than negative individuals [5]. Comparable results were obtained in the subgroup analysis of CheckMate 459, where individuals treated with nivolumab who obtained PD-L1 ≥ 1% were prone to experience longer median OS than those who did not [14]. In the KEYNOTE-224 study, the combined positive score (CPS) ≥ 1 was found to be a better predictor of high ORR and PFS compared to the tumor proportion score (TPS ≥ 1%) [6]. The phase 1b study (GO30140) [15] and phase II study (NCT02989922, camrelizumab) [43]. According to Bassaganyas and colleagues, high broad CNAs are linked to immune exclusion and proliferation, and the CNA broad score could predict ICI therapy response in HCC [44].
The TP53 gene has been linked to the immune environment in HCC. As compared to individuals with wild-type TP53, those possessing TP53 mutations exhibited a shorter OS and recurrence-free survival [45]. CTNNB1 is another gene of interest, and basic research determined its role in immune escape and anti-PD-1 resistance [46]. It may function as a biomarker of immune rejection in individuals with aHCC. A small cohort enrolled HCC patients treated with ICIs showed that poor prognosis was related to altered WNT/β-catenin signaling, showing decreased disease control rate (0% vs. 53%), shorter median PFS (2.0 vs. 7.4 months), and shorter median OS (9.1 vs. 15.2 months) [47]. Additional investigations are suggested to comprehend its underlying mechanism on immunotherapy resistance [47, 48]. The GO30140 study showed that high expression of immune genes (CD274) and effector T signaling genes (GZMB, PRF1, and CXCL9) was linked with highly satisfying outcomes, including ORR and PFS. On the contrary, high expression of Notch pathway activation genes was a negative predictor [49]. The Checkmate 040 study subgroup results revealed that better ORR and OS were linked with high expression of inflammatory gene signals (CD274, CD8A, LAG3, and STAT1) [22].
Clinical features of tumors
Tumor burden
The macroscopic features of a tumor, such as its size and location, are more easily noticeable to a clinician than its microscopic features.
The size of a tumor is a crucial prognostic factor. A study of 33 nivolumab-treated patients found that those with tumors smaller than 5 cm (P = 0.034) and albumin-bilirubin (ALBI) scores of 1 (P = 0.040) had a better prognosis [50]. The results remained significant in a multivariate analysis for tumors smaller than 5 cm and ALBI scores of 1. Another study of 261 patients with HCC in Korea showed that those with small tumors (< 10 cm) had a high likelihood of responding to therapy (11.4% vs. 5.5%) and better PFS and OS (P < 0.05) [51]. Moreover, Huang et al. found that in cases of multifocal HCC, small lesions had strong immune infiltration and were responsive to PD-1 inhibitors [109]. A subsequent phase III confirmatory study made clear that Sin/Bev greatly improved median OS and PFS in comparison to sorafenib [110].
PD-1/PD-L1 inhibitors combined with TKIs
Several large phase III RCTs of PD-1/PD-L1 inhibitors bonded with TKIs have been conducted, but the efficacy of this regimen compared with TKI monotherapy is controversial. For the portfolio of camrelizumab plus apatinib, a phase II RCT showed that the ORR in the first-line cohort was 34.3% and 22.5% in the second-line cohort, showing good therapeutic effects [111]. The subsequent phase III CARES-310 trial showed that compared with sorafenib, camrelizumab plus rivoceranib (also referred to as apatinib) therapy led to a 48% reduction in the risk of disease progression (median PFS: 5.6 vs. 3.7 months) and a 38% reduction in the risk of death (median OS: 22.1 vs. 15.2 months) [112]. In the LEAP-002 trial, lenvatinib combined with pembrolizumab showed an improvement in PFS over lenvatinib monotherapy, although the results did not satisfy the validity threshold [113]. Similarly, cabozantinib plus atezolizumab offered improved PFS compared with sorafenib alone but without improving OS [114]. According to a phase II RCT conducted recently in naive-treatment patients, tislelizumab combined with lenvatinib achieved a 38.7% ORR and a 9.7-month median PFS [115]. Additional clinical trials are being conducted to assess the effectiveness of this regimen.
PD-1/PD-L1 inhibitor combined with CTLA-4 inhibitor
In another CheckMate 040 sub-cohort, different doses of nivolumab combined with ipilimumab were used to treat sorafenib-resistant aHCC. Approximately 30% of the cases responded to this regimen with a median OS of 22.8 months [17]. The latest HIMALAYA trial showed excellent efficacy of the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen. STRIDE significantly outperformed sorafenib in OS (median OS: 16.4 vs. 13.8 months). However, tumor responses were substantially better with sorafenib, which presented a 22-month median duration of response [19]. Additional details on these critical trials are summarized in Table 3.
The recently developed bispecific antibody (BsAb) drug (i.e., AK104) has shown potential in solid tumors [116]. Consequently, research on such agents is being conducted in aHCC. Additionally, novel combinations of immunotherapeutic agents are being explored for the treatment of aHCC, with a focus on newly developed ICIs such as TIGIT and LAG3 inhibitors. The umbrella study (NCT04524871) serves as a representative example of these endeavors. Furthermore, several prospective clinical studies focus on the combinations of local therapies (e.g., transarterial chemoembolization) with immunotherapy in intermediate HCC. Noteworthy studies in this area include LEAP-012, ABC-HCC, and EMERALD. The effectiveness of this regimen has already been demonstrated in the retrospective study [39]. Moreover, prospective research on the combination of stereotactic radiation therapy with immunotherapy is currently unfolding. The key ongoing clinical trials studying immunotherapies for unresectable HCC are listed in Table 4.
Conclusions and perspectives
Systemic therapy using PD-1/PD-L1 inhibitors has been shown to be effective in treating HCC; however, this treatment is only beneficial to a subset of patients. Therefore, biomarker analysis is crucial for identifying individuals who will most likely respond to this treatment. A summary of the aforementioned biomarkers is shown in Fig. 1 and Supplementary Table 1.
The summary of the biomarkers in PD-1/PD-L1 inhibitor-based therapy in aHCC. Current studies on biomarkers are focused on the tumor microenvironment, tumor genomics, tumor clinical features, host clinical features, liquid biopsy, and gut microbiota. Abbreviations: AFP, alpha-fetoprotein; aHCC, advanced hepatocellular carcinoma; ALBI, albumin-bilirubin; cfDNA, cell-free DNA; CNAs, copy number alterations; CTC, circulating tumor cell; ctDNA, circulating tumor DNA; ECOG, Eastern Cooperative Oncology Group; EOB-MRI, Gd-EOB-DTPA-enhanced magnetic resonance imaging; HBV, hepatitis B virus; HCV, hepatitis C virus; IL-6, interleukin-6; IO, immunotherapy; irAE, immune-related adverse event; LDH, lactate dehydrogenase; MRE, magnetic resonance elastography; NLR, neutrophil-lymphocyte ratio; PD-1, programmed death-1; PD-L1, programmed death ligand 1; PET/CT, positron emission tomography-computed tomography; PG-SGA, patient-generated subjective global assessment; PIVKA-II, abnormal prothrombin; PLR, platelet-to-lymphocyte ratio; TBS, tumor burden score; TGF-β, Transforming Growth Factor beta; TIB, tumor immune barrier; TILs, tumor-infiltrating lymphocytes; Treg, regulatory T cell; TMB, tumor mutational burden
Despite the importance of biomarkers in HCC, their use faces several challenges. First, the methods used for immunotherapy lack uniformity. As more studies combine PD-1/PD-L1 inhibitors with TKI/VEGF therapy, the underlying mechanisms and effectiveness may vary. Second, although some cases of HCC can be diagnosed through imaging, pathological tissue may not be available in all cases, thus increasing the difficulty of analyzing the immune microenvironment. Limited biomarkers are available for dynamic monitoring, and data are scarce for adjusting treatment after drug resistance.
With continued advances in research on HCC immunotherapy, mainly through extensive sample studies and subsequent subgroup analyses, biomarkers will hopefully become more widespread, which will allow for earlier identification of the target population. In the future, cutting-edge non-invasive monitoring methods (such as ctDNA), imaging parameters (such as PET/CT), and multi-dimensional information from artificial intelligence radiomics and single-cell sequencing sources may help us to comprehensively understand the mechanisms behind HCC immunotherapy response and the causes of drug resistance. These findings will ultimately result in more tailored treatment options.
Data Availability
The material supporting the information in this review has been included in this article.
Abbreviations
- 18F-FDG:
-
18F-fluorodeoxyglucose
- 68Ga-FAPI:
-
68Ga-labeled FAP inhibitor
- AFP:
-
Alpha-fetoprotein
- aHCC:
-
Advanced hepatocellular carcinoma
- ALBI:
-
Albumin-bilirubin
- Atezo/Bev:
-
Atezolizumab and bevacizumab
- BsAb:
-
Bispecific antibody
- CCF:
-
ctDNA content fraction
- cDC1:
-
conventional DC 1
- cfDNA:
-
cell-free DNA
- CNA:
-
Copy number alteration
- CNV:
-
Copy number variation
- CPS:
-
Combined positive score
- CR:
-
Complete response
- CRP:
-
C-reactive protein
- CTCs:
-
Circulating tumor cells
- ctDNA:
-
circulating tumor DNA
- CTLA-4:
-
Cytotoxic T lymphocyte–associated antigen 4
- CYT:
-
Cytolytic Activity Score
- CAFs:
-
Cancer-associated fibroblasts
- dNLR:
-
derived neutrophil-lymphocyte ratio
- ECOG:
-
Eastern Cooperative Oncology Group
- Gd-EOB-DTPA:
-
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
- EOB-MRI:
-
Gd-EOB-DTPA-enhanced magnetic resonance imaging
- HCC:
-
Hepatocellular carcinoma
- HPD:
-
Hyperprogressive disease
- ICI:
-
Immune checkpoint inhibitor
- IFN-γ:
-
Interferon γ
- IL-6:
-
Interleukin-6
- irAEs:
-
immune-related adverse events
- LDH:
-
Lactate dehydrogenase
- MRE:
-
Magnetic resonance elastography
- nsSNVs:
-
nonsense single nucleotide mutations
- ORR:
-
Objective response rate
- OS:
-
Overall survival
- PD-1:
-
Programmed death-1
- PD-L1:
-
Programmed death ligand 1
- PET/CT:
-
Positron emission tomography-computed tomography
- PFS:
-
Progression-free survival
- PG-SGA:
-
Patient-generated subjective global assessment
- PIVKA-II:
-
Prothrombin induced by vitamin K absence-II
- PLR:
-
Platelet-to-lymphocyte ratio
- PR:
-
Partial response
- RCTs:
-
Randomized clinical trials
- RLTCC:
-
Ratio of lymphocyte to total cell count
- SD:
-
Stable disease
- SDC:
-
Stimulatory dendritic cell
- STRIDE:
-
Single Tremelimumab Regular Interval Durvalumab
- TBS:
-
Tumor burden score
- TCGA-LIHC:
-
The Cancer Genome Atlas Program Liver Hepatocellular Carcinoma
- TILs:
-
Tumor-infiltrating lymphocytes
- TIB:
-
Tumor immune barrier
- TIGIT:
-
T cell immunoglobulin and ITIM domain
- TKIs:
-
Tyrosine kinase inhibitors
- TMB:
-
Tumor mutational burden
- TME:
-
Tumor microenvironment
- Treg:
-
Regulatory T cell
- TPS:
-
Tumor proportion score
- VEGF:
-
Vascular endothelial growth factor
References
European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L. EASL Clinical Practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
Villanueva A, Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–62.
Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, et al. Guidelines for diagnosis and treatment of primary Liver Cancer in China (2017 Edition). Liver Cancer. 2018;7(3):235–60.
Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–32.
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502.
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–52.
Sangro B, Park J, Finn R, Cheng A, Mathurin P, Edeline J, et al. LBA-3 CheckMate 459: long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. Ann Oncol. 2020;31:241–S2.
Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as Second-Line therapy in patients with Advanced Hepatocellular Carcinoma in KEYNOTE-240: a Randomized, Double-Blind, phase III trial. J Clin Oncol. 2019. Jco1901307.
Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, et al. CXCR4 inhibition in Tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology. 2015;61(5):1591–602.
Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A et al. Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC. Hepatology. 2019.
Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX et al. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer. 2020;8(2).
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–905.
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–50.
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus Sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90.
Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808–20.
Qin S, Ren Z, Meng Z, Chen Z, Chai X, **ong J, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571–80.
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B et al. Efficacy and safety of Nivolumab Plus Ipilimumab in patients with Advanced Hepatocellular Carcinoma previously treated with Sorafenib: the CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020.
Lee DW, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH et al. Phase II study of Avelumab in patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clin Cancer Res. 2020.
Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.
Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, Tumor mutational burden, and beyond. J Immunother Cancer. 2018;6(1):4.
Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017;171(4):934–49e16.
Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020;73(6):1460–9.
Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545–51.
Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B et al. Immunohistochemical scoring of CD38 in the Tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma. J Immunother Cancer. 2020;8(2).
Lee H-S, Kang KKG, Jung K-H, Kaseb AO, Lee SS. Quantitative analysis of spatial distribution of lymphocytes in hepatocellular carcinoma: a biomarker correlated with survival and gene expression in cancer immune system. J Clin Oncol. 2022;40(abstr 4119).
Agdashian D, ElGindi M, **e C, Sandhu M, Pratt D, Kleiner DE, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68(4):599–608.
Balli D, Rech AJ, Stanger BZ, Vonderheide RH. Immune Cytolytic Activity Stratifies Molecular subsets of Human Pancreatic Cancer. Clin Cancer Res. 2017;23(12):3129–38.
Narayanan S, Kawaguchi T, Yan L, Peng X, Qi Q, Takabe K. Cytolytic activity score to assess Anticancer Immunity in Colorectal Cancer. Ann Surg Oncol. 2018;25(8):2323–31.
Takahashi H, Kawaguchi T, Yan L, Peng X, Qi Q, Morris LGT et al. Immune Cytolytic Activity for Comprehensive understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers (Basel). 2020;12(5).
Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the Tumor Site enhances Tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924–38.
Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive Tumor microenvironments. Nat Med. 2018;24(8):1178–91.
Zhu AX, Guan Y, Abbas AR, Koeppen H, Lu S, Hsu C-H, et al. Abstract CT044: genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC). Cancer Res. 2020;80(16Supplement):CT044–CT.
Cui X, Han L, Cui L, Fu G, Liu E, Wang D, et al. Immune index: a gene and cell prognostic signature for immunotherapy response prediction in hepatocellular carcinoma. Pharmacol Res. 2023;187:106583.
Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, et al. Tumor Cell Biodiversity drives Microenvironmental Reprogramming in Liver Cancer. Cancer Cell. 2019;36(4):418–30e6.
Ma L, Wang L, Khatib SA, Chang CW, Heinrich S, Dominguez DA, et al. Single-cell atlas of Tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Hepatol. 2021;75(6):1397–408.
Xue R, Zhang Q, Cao Q, Kong R, **ang X, Liu H, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;612(7938):141–7.
Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78(4):770–82.
Zhang S, Yuan L, Danilova L, Mo G, Zhu Q, Deshpande A, et al. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies Independent mechanisms of resistance and recurrence. Genome Med. 2023;15(1):72.
Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8(1):58.
Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, et al. Randomized Phase 3 LEAP-012 study: Transarterial Chemoembolization with or without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma not amenable to curative treatment. Cardiovasc Intervent Radiol. 2022;45(4):405–12.
Ben Khaled N, Seidensticker M, Ricke J, Mayerle J, Oehrle B, Rössler D, et al. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future Oncol. 2022;18(12):1423–35.
Li L, Rao X, Wen Z, Ding X, Wang X, Xu W, et al. Implications of driver genes associated with a high Tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma. Oncol Lett. 2020;19(4):2739–48.
Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616.
Bassaganyas L, Pinyol R, Esteban-Fabró R, Torrens L, Torrecilla S, Willoughby CE, et al. Copy-number Alteration Burden differentially impacts Immune profiles and Molecular features of Hepatocellular Carcinoma. Clin Cancer Res. 2020;26(23):6350–61.
Long J, Wang A, Bai Y, Lin J, Yang X, Wang D, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019;42:363–74.
Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, Lindblad KE, Maier B, Sia D, et al. beta-catenin activation promotes Immune Escape and resistance to Anti-PD-1 therapy in Hepatocellular Carcinoma. Cancer Discov. 2019;9(8):1124–41.
Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M et al. Prospective genoty** of Hepatocellular Carcinoma: clinical implications of Next Generation sequencing for matching patients to targeted and Immune therapies. Clin Cancer Res. 2018.
von Felden J, Craig AJ, Garcia-Lezana T, Labgaa I, Haber PK, D’Avola D et al. Mutations in circulating Tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene. 2020.
Zhu AX, Guan Y, Abbas AR, Koeppen H, Lu S, Hsu C-H, et al. Abstract CT044: genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC). Cancer Res. 2020;80(16 Supplement):CT044.
Sung PS, Jang JW, Lee J, Lee SK, Lee HL, Yang H, et al. Real-world outcomes of Nivolumab in patients with Unresectable Hepatocellular Carcinoma in an endemic area of Hepatitis B Virus Infection. Front Oncol. 2020;10:1043.
Kim HS, Hong JY, Cheon J, Kim I, Kim CG, Kang B, et al. Different organ-specific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC). J Clin Oncol. 2020;38(15suppl):4584.
Huang M, He M, Guo Y, Li H, Shen S, **e Y, et al. The influence of Immune Heterogeneity on the effectiveness of Immune checkpoint inhibitors in Multifocal Hepatocellular Carcinomas. Clin Cancer Res. 2020;26(18):4947–57.
Yang X, Chen B, Wang Y, Wang Y, Long J, Zhang N et al. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients. Hepatol Int. 2023:1–11.
Lu LC, Hsu C, Shao YY, Chao Y, Yen CJ, Shih IL, et al. Differential Organ-Specific Tumor response to Immune checkpoint inhibitors in Hepatocellular Carcinoma. Liver Cancer. 2019;8(6):480–90.
Kuo HY, Chiang NJ, Chuang CH, Chen CY, Wu IC, Chang TT, et al. Impact of Immune Checkpoint inhibitors with or without a combination of tyrosine kinase inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma. Oncol Res Treat. 2020;43(5):211–20.
Choi WM, Lee D, Shim JH, Kim KM, Lim YS, Lee HC et al. Effectiveness and safety of Nivolumab in child-pugh B patients with Hepatocellular Carcinoma: a real-world cohort study. Cancers (Basel). 2020;12(7).
Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y et al. Immunotherapy in Hepatocellular Cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI Grade. Cancers (Basel). 2020;12(7).
Fessas P, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T et al. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. J Immunother Cancer. 2020;8(2).
Hung HC, Lee JC, Wang YC, Cheng CH, Wu TH, Lee CF et al. Response prediction in Immune checkpoint inhibitor immunotherapy for Advanced Hepatocellular Carcinoma. Cancers (Basel). 2021;13(7).
Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450–6.
Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353–63.
Yang Y, Ouyang J, Zhou Y, Zhou J, Zhao H. The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations. J Hepatol. 2022;77(2):574–6.
Feun LG, Li YY, Wu C, Wangpaichitr M, Jones PD, Richman SP, et al. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer. 2019;125(20):3603–14.
Chen S, Huang Z, Jia W, Tao H, Zhang S, Ma J, et al. Association of the pretreatment lung Immune Prognostic Index with Survival outcomes in Advanced Hepatocellular Carcinoma patients treated with PD-1 inhibitors. J Hepatocell Carcinoma. 2020;7:289–99.
Myo** Y, Kodama T, Sakamori R, Maesaka K, Matsumae T, Sawai Y et al. Interleukin-6 is a circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with combined immunotherapy. Cancers (Basel). 2022;14(4).
Ueno A, Masugi Y, Yamazaki K, Komuta M, Effendi K, Tanami Y, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol. 2014;61(5):1080–7.
Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, et al. Higher enhancement intrahepatic nodules on the Hepatobiliary phase of Gd-EOB-DTPA-Enhanced MRI as a poor responsive marker of Anti-PD-1/PD-L1 monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer. 2021;10(6):615–28.
Sasaki R, Nagata K, Fukushima M, Haraguchi M, Miuma S, Miyaaki H et al. Evaluating the role of Hepatobiliary Phase of Gadoxetic Acid-enhanced magnetic resonance imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2022;14(3).
Qayyum A, Hwang KP, Stafford J, Verma A, Maru DM, Sandesh S, et al. Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. J Immunother Cancer. 2019;7(1):329.
Qayyum A, Avritscher R, Aslam R, Ma J, Pagel MD, Sun J, et al. Immune checkpoint blockade (ICB) response evaluation with MRI/MR elastography (MRE) in surgical and nonsurgical patients with HCC. J Clin Oncol. 2020;38(4suppl):480.
Wang G, Zhang W, Chen J, Luan X, Wang Z, Wang Y, et al. Pretreatment metabolic parameters measured by (18)F-FDG PET to predict the pathological treatment response of HCC patients treated with PD-1 inhibitors and Lenvatinib as a Conversion Therapy in BCLC Stage C. Front Oncol. 2022;12:884372.
Wang X, Yang X, Wang J, Dong C, Ding J, Wu M, et al. Metabolic Tumor volume measured by (18)F-FDG PET/CT is Associated with the survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 inhibitors plus molecular targeted agents. J Hepatocell Carcinoma. 2023;10:587–98.
Ho G, Chen S, Wong YH, Yip Y, Yung WH, Leung WT. <strong> Choice of Tyrosine Kinase Inhibitor (TKI) or Immune Check-point Inhibitor guided by dual-tracer (11 C-acetate and 18F-FDG) PET/CT improves the progression-free survival in patients with advanced or metastatic HCC</strong>. J Nucl Med. 2022;63(supplement 2):2376.
Wu M, Wang Y, Yang Q, Wang X, Yang X, **ng H, et al. Comparison of baseline (68)Ga-FAPI and (18)F-FDG PET/CT for prediction of response and clinical outcome in patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 inhibitor and Lenvatinib. J Nucl Med. 2023;64(10):1532–9.
Shao YY, Liu TH, Hsu C, Lu LC, Shen YC, Lin ZZ et al. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int. 2019.
Sun X, Mei J, Lin W, Yang Z, Peng W, Chen J, et al. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer. 2021;21(1):775.
Dharmapuri S, Özbek U, Lin JY, Sung M, Schwartz M, Branch AD, et al. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy. Cancer Med. 2020;9(14):4962–70.
Kim CG, Kim C, Yoon SE, Kim KH, Choi SJ, Kang B et al. Hyperprogressive Disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol. 2020.
Ng KYY, Tan SH, Tan JJE, Tay DSH, Lee AWX, Ang AJS, et al. Impact of Immune-related adverse events on efficacy of Immune checkpoint inhibitors in patients with Advanced Hepatocellular Carcinoma. Liver Cancer. 2022;11(1):9–21.
Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, et al. Association of Anti-programmed Cell Death 1 cutaneous toxic effects with outcomes in patients with Advanced Melanoma. JAMA Oncol. 2019;5(6):906–8.
Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell Lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol. 2019;145(2):479–85.
Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, et al. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study. Eur J Cancer. 2020;134:19–28.
Ao H, **n Z, Jian Z. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma. Biomark Res. 2021;9(1):91.
Winograd P, Hou S, Court CM, Lee YT, Chen PJ, Zhu Y, et al. Hepatocellular Carcinoma-circulating Tumor cells expressing PD-L1 are prognostic and potentially Associated with response to checkpoint inhibitors. Hepatol Commun. 2020;4(10):1527–40.
Li J, Jiang W, Wei J, Zhang J, Cai L, Luo M, et al. Patient specific circulating Tumor DNA fingerprints to monitor treatment response across multiple tumors. J Transl Med. 2020;18(1):293.
Hsu C-H, Lu S, Abbas A, Guan Y, Zhu AX, Aleshin A, et al. Longitudinal and personalized detection of circulating Tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2020;38(15suppl):3531.
Franses JW, Lim M, Burgoyne AM, Mody K, Lennerz J, Chang J, et al. Profile and predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma. Oncologist. 2022;27(11):e908–e11.
Yang X, Hu Y, Yang K, Wang D, Lin J, Long J et al. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. J Immunother Cancer. 2021;9(5).
Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80–6.
Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer Immunosurveillance. Cell. 2016;165(2):276–87.
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and Colitis in metastatic Melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368–79.
Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019;7(1):193.
Mao J, Wang D, Long J, Yang X, Lin J, Song Y et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer. 2021;9(12).
Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2022;10(6).
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.
Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, et al. Donafenib Versus Sorafenib in First-Line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, Open-Label, parallel-controlled phase II-III trial. J Clin Oncol. 2021;39(27):3002–11.
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54–63.
Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6(7):559–68.
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after Sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–96.
Yau T, Park JW, Finn RS, Cheng A-L, Mathurin P, Edeline J et al. LBA38_PRCheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30(Supplement_5).
Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH, et al. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer. 2022;167:1–12.
Merle P, Kudo M, Edeline J, Bouattour M, Cheng A-L, Chan SL et al. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: longer term Follow-Up from the phase 3 KEYNOTE-240 trial. Liver Cancer. 2023:1–12.
Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo B-Y, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study. J Clin Oncol. 2022;40(4suppl):383.
Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z et al. Tislelizumab vs Sorafenib as First-Line treatment for Unresectable Hepatocellular Carcinoma: a phase 3 Randomized Clinical Trial. JAMA Oncol. 2023.
Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus Bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–73.
Ryoo B-Y, Hsu C-H, Li D, Burgoyne A, Cotter C, Badhrinarayanan S, et al. Results from the MORPHEUS-liver study: phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC). J Clin Oncol. 2023;41(16suppl):4010.
Jia F, Ren Z, Xu J, Shao G, Dai G, Liu B, et al. 991P sintilimab plus IBI305 as first-line treatment for advanced hepatocellular carcinoma. Ann Oncol. 2020;31:692.
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 2021;22(7):977–90.
Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, et al. Camrelizumab in Combination with Apatinib in patients with Advanced Hepatocellular Carcinoma (RESCUE): a nonrandomized, Open-label, phase II trial. Clin Cancer Res. 2021;27(4):1003–11.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus Rivoceranib versus Sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133–46.
Finn RS, Merle MKP, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo B, Ren Z, Cheng A, Galle PR, Kaneko S, Kumada H, Wang A, Mody K, Dubrovsky L, Siegel AB. Llovet. Primary results from the phase III LEAP-002 study: Lenvatinib plus Pembrolizumab versus Lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022;33:808–S69.
Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus Atezolizumab versus Sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008.
Xu L, Yang JCJ, Gong W, Zhang Y, Zhao H, Yan S, Jia W, Wu Z, Liu C, Song X, Ma Y, Yang X, Gao Z, Zhang N, Zheng X, Li M, Zhang X, Chen M. Efficacy and safety of tislelizumab (TIS) plus lenvatinib (LEN) as first-line treatment in patients (pts) with unresectable hepatocellular carcinoma (uHCC): a single-arm, multicenter, phase II trial. Immuno-Oncology and Technology. 2022;16(S1):24–5.
Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial. Lancet Oncol. 2023;24(10):1134–46.
Acknowledgements
Not applicable.
Funding
This work was supported by National High Level Hospital Clinical Research Funding[2022-PUMCH-B-128], CAMS Innovation Fund for Medical Sciences(CIFMS)[2022-I2M-C&T-A-003], CAMS Innovation Fund for Medical Sciences (CIFMS) [2021-I2M-1-061] [2021-I2M-1-003] and National Ten-thousand Talent Program.
Author information
Authors and Affiliations
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Zhang, N., Yang, X., Piao, M. et al. Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomark Res 12, 26 (2024). https://doi.org/10.1186/s40364-023-00535-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s40364-023-00535-z